TUMOR ANTIGEN CA125 IN OVARIAN CANCER PATIENTS

卵巢癌患者的肿瘤抗原 CA125

• 批准号: 3180275
• 负责人: TIMOTHY J O'BRIEN
• 金额: $ 11.18万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-04-01 至 1989-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3180275
• 关键词: adenocarcinoma; amniotic fluid; antibody; chorioallantoic membrane; gene expression; genetic library; human tissue; messenger RNA; molecular cloning; neoplasm /cancer genetics; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunology; neoplasm /cancer relapse /recurrence; neoplastic cell; oligonucleotides; ovary neoplasms; tumor antigens

The necessity for tumor markers which reflect tumor burden, patient response to therapy, and provide early indications of recurrent disease is an important and significant component for the present management of cancer patients. For gynecologic tumors no such markers existed. At this time, at least one promising tumor antigen CA125 has been documented and evaluated for use in serous ovarian cystadenocarcinomas. For ovarian cancer patients this finding has pertinence because of the latent nature of the disease in women in their post menopausal years. The proposal addresses the expression and characterization of CA125 in malignant ovarian carcinomas in benign disease and in normal tissues. Such information can impact a new understanding of continued or renewed expression of the gene in malignancy along with control of expression of the gene in normal tissue. It is proposed to study CA125 by utilizing a newly discovered source of the antigen in normal human tissues which previously was found only in trace amounts in mullerian duct derivatives. We have data which provides an insight into the subunit composition of the CA125 molecule and have developed polyclonal antibodies to the whole molecule. It is proposed to use this information and the polyclonal antibody reagent to evaluate the sub unit composition of the molecule from normal, benign and malignant tissues, to obtain sufficient amino acid sequence data for some of the subunits to be able to synthesize polynucleotide oligomers. These reagents will be used to probe a CDNA library made from chorion where a substantial concentration of CA125 antigen is located. The CDNA clones will be characterized for authenticity and used to screen and quantitate mRNA from normal and malignant tissues. In the future these probes will be further used to elucidate the structure and expression of the CA125 gene(s).

反映患者肿瘤负荷的肿瘤标志物的必要性 对治疗的反应，并提供复发性疾病的早期迹象 当前癌症治疗的重要组成部分 患者。 对于妇科肿瘤，不存在这样的标记。 此时， 至少一种有前途的肿瘤抗原 CA125 已被记录并且 评估用于浆液性卵巢囊腺癌。 对于卵巢 对于癌症患者，这一发现具有相关性，因为其潜在的性质 绝经后妇女的疾病。 提案 解决恶性卵巢中 CA125 的表达和特征 良性疾病和正常组织中的癌症。 此类信息可以 影响对基因持续或更新表达的新理解 在恶性肿瘤中以及在正常情况下控制基因表达 组织。 建议利用新发现的一种物质来研究CA125 先前在正常人体组织中发现的抗原来源 仅在苗勒氏管衍生物中存在微量。 我们有数据 提供对 CA125 分子亚基组成的深入了解 已开发出针对整个分子的多克隆抗体。 建议 使用此信息和多克隆抗体试剂来评估 正常、良性和恶性分子的亚单位组成 组织，以获得一些足够的氨基酸序列数据 亚基能够合成多核苷酸寡聚体。 这些试剂 将用于探测由绒毛膜制成的 cDNA 文库，其中大量 定位CA125抗原的浓度。 cDNA 克隆将是 鉴定其真实性并用于筛选和定量来自 正常和恶性组织。 未来这些探索将进一步深入 用于阐明 CA125 基因的结构和表达。